Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Reprod Nutr Dev ; 43(4): 347-56, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14971826

RESUMEN

According to Burkitt's hypothesis, dietary fibres may protect against the development of colorectal cancer. In rats, studies have shown that only butyrate-producing fibres are protective. In parallel, in humans, non-steroidal anti-inflammatory drugs, which target cyclooxygenases, have been shown to display a protective effect against colorectal cancer. Among them, COX-2-selective inhibitors which present less side effects than non-selective agents, are promising as chemopreventive agents. Our aim was to analyse the effect of an association between butyrate-producing fibres and the COX-2 inhibitor on the development of aberrant crypt foci (ACF) in rats. Fisher F344 rats were fed with (1) a standard low fibre control diet; (2) the standard diet supplemented with 1500 ppm celecoxib; (3) a diet supplemented with 6% fructo-oligosaccharide (FOS); and (4) a diet with both celecoxib and FOS. Three weeks later, the rats were injected twice with azoxymethane and the number of ACF was determined 15 weeks later. In the control group, 43.8 +/- 6.4 ACF were found. This number was not significantly modified by the addition of FOS or celecoxib alone to the diet. However, the association of FOS and celecoxib resulted in a 61% reduction in the number of ACF (P < 0.01). The number of aberrant crypt per foci was also reduced. Thus, although no significant effect of celecoxib or FOS alone was identified, the association of butyrate-producing fibre and celecoxib was effective in preventing the development of ACF. This preliminary study argues for a strong protective effect of such an association which deserves further studies.


Asunto(s)
Anticarcinógenos/administración & dosificación , Colon/patología , Fibras de la Dieta/administración & dosificación , Oligosacáridos/administración & dosificación , Sulfonamidas/administración & dosificación , Animales , Azoximetano/antagonistas & inhibidores , Butiratos/metabolismo , Celecoxib , Colon/efectos de los fármacos , Colon/metabolismo , Neoplasias del Colon/inducido químicamente , Neoplasias del Colon/prevención & control , Inhibidores de la Ciclooxigenasa/farmacología , Masculino , Neoplasias Experimentales , Oligosacáridos/metabolismo , Pirazoles , Distribución Aleatoria , Ratas , Ratas Endogámicas F344
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA